Molecule

In early March, we met with the SEC Crypto Task Force. We presented a framework we've been building toward for a long time: a documented, legally grounded pathway from token community participation to genuine equity ownership. Most crypto ecosystems face some version of this tension, but in Decentralized Science, it's especially critical, because we're dealing with real-world assets in the form of biotech intellectual property. Resolving this tension has long been on our horizon, which is why we're proud to announce our Coin-to-Company model, already in use by @vitadao, as we continue the regulatory conversation with the SEC. The C2C model works through a categorical separation of tokens and equity securities, treating them as different but complementary instruments that can operate together across company formation, funding, and administration. Through a token locking mechanism, community members can choose to convert their participation into actual shareholder status in the underlying biotech company. All tokenholders remain part of a project-focused DAO throughout. The result is a structure that delivers genuine ownership upside, protects community members from personal liability, opens the door to global participation, and gives any project a replicable playbook to follow, while keeping the open, community-driven ecosystem that makes the space compelling in the first place. The meeting does not constitute any formal SEC endorsement, but it was productive, and we were glad to start the dialogue. Read the announcement & let us know what you think.

PeptAI has launched -- 32X+ oversubscribed, 1.6M+ USDC committed by 1.4K+ participants. A fleet of autonomous AI agents designing and validating new peptide drug candidates, with every decision published openly on Molecule Labs in real time. Each candidate has to clear a 9-gate pipeline before reaching the wet lab. Eight computational gates, one wet-lab gate. Pass, and the agent advances the candidate. Fail, and it's redesigned or discarded. Every decision is published the moment it happens, traceable end-to-end. The fleet is currently running programmes against receptors tied to metabolic health, fertility, and ADHD, with a community-selected target queued next. What makes this work is the infrastructure underneath. PeptAI pays from its own wallet for wet-lab experiments when gate milestones are reached, runs validation through @adaptyvbio for synthesis and binding assays, pulls literature and novelty checks from BIOS via @bioaidevs, runs molecular dynamics through @try_litefold, and settles machine-to-machine payments on @base. Molecule Labs is the connective tissue, publishing every gate decision, every candidate, every result as it happens. This is what the infrastructure layer is supposed to do. Give a fully autonomous research program a place to operate transparently, pay its own bills, and let anyone in the world verify the science as it unfolds. PeptAI is experimental and actively evolving. Gates, tools, and thresholds will change as the agents learn from each run. Follow along here for live updates as the fleet runs. Explore PeptAI peptai.xyz Token app.bio.xyz/agents/peptai Follow @peptai_ for live gate decisions

Latest piece from @beakerdao traces the story of DeSci back to Molecule in 2020, when the first biopharma research asset moved onchain, with @VitaDAO as the proof of concept that built the template for everything since. Makes us excited for the future!

What's next for PeptAI? - Q2 2026: First on-chain wet-lab attestation via @Molecule_sci Labs - Q3 2026: Autonomous iteration cycle proven, GLP-1R Gen 1 library, design-vs-nature bioRxiv preprint - Q4 2026: Pipeline scales beyond GPCRs - Q1 2027: Lead optimization at scale, pre-IND scoping - Q2 2027: First in vivo studies, multi-target portfolio in parallel Follow @peptai_ for live gate decisions, candidate updates, and wet-lab results.

The real-world asset conversation has been almost entirely about bringing liquid financial products onchain. The harder and more interesting version is bringing productive assets onchain, research programs, intellectual property, projects that need active management and can develop value over years.

That's what Molecule has been building toward, and it's what the Coin-to-Company model unlocks: a compliant bridge from token community to company equity, for the category of RWAs that actually require one. Framework breakdown on the blog → molecule.xyz/blog/compliant…

Beach Science started as an experiment in agentic research. In under 8 weeks, 59 AI agents and 55 researchers generated 6,134 hypotheses in public. The experiment worked. And now it's evolving. The generation part works. Most of the 6,134 hypotheses sat without review. A few moved forward, but only because a specific person noticed them and manually pushed them through. A few things still don't exist: → A shared place where humans and agents actually work together. Interest and conviction stay invisible everywhere else. → Small capital that can find small science. The payment rails are in place (x402, @molecule_sci, @bioprotocol). The layer that routes them to specific experiments still has to be built. → A way for the best ideas to actually surface. Right now, strong claims and weak ones look the same in the feed. Beach Science is evolving into the layer where strong claims attract collaborators, build conviction, and reach capital without waiting on someone to push them through. Claim, conviction, and capital collapsed into a single motion. Everything posted on @sciencebeach__ carries forward. More on this soon.

How everything the agents do gets tracked, verified, and made public. Every gate decision, tool call, pass, and failure is published openly on @Molecule_sci Labs. > Agents mint their own IP NFTs and log the full audit trail on-chain. > Computational analysis stays publicly verifiable. > Wet lab results can be held private until the team decides on disclosure. Agent announcements on new library designs and gate outcomes will publish on a weekly cadence to start.

Read the full piece here → bankless.com/read/ai-rewrit… View @peptai_ on Molecule → peptai.xyz

Recently @Bankless did a piece on where DeSci goes next as AI collapses the cost of drug discovery. Molecule Labs is called out as the open data layer that the ecosystem has been missing. The argument from @davewardonline: drug development has always been gated at the earliest stage by capital, not by science. When discovery costs collapse, a research collective can fund a candidate all the way to real lab data. That opens up categories of research pharma was never going to touch. The biology behind ADHD's orexin system has been documented for years, but no institution with the capital has spent time developing it. An AI scientist called @peptai_ did, in roughly 24 hours. @peptai_ is using Molecule Labs to manage the work. Every research program's data, IP, and treasury lives in one place, openly tracked. Milestones, results, and failed experiments stay on the record. Future researchers and AI agents build on the work.

Read it here → molecule.xyz/blog/compliant…

Blockchain tech has always moved faster than the law. For most of the last decade, projects funding real research have been working from predictions about how regulators might eventually treat tokens and equity, which is a fragile foundation for serious science. Instead of predicting where regulation will land, Molecule's Coin-to-Company uses securities frameworks that already exist and have governed U.S. startups for decades, applied deliberately to a dual-track structure of tokens and equity. A full walkthrough of how it works and the precedent it builds on is live on our website.

Introducing PeptAI: Autonomous Agents for Peptide Drug Discovery x.com/i/broadcasts/1…

Peptides are one of the most active frontiers in drug discovery right now. Agents like @peptai_ can accelerate the search, but the work still has to be auditable. Molecule Labs is the verifiable layer: programs, data, milestones, openly tracked. Join the livestream!

Gates are opening soon.

Read the full piece here → bankless.com/read/ai-rewrit…

New piece from @Bankless on how AI is rewriting the economics of drug discovery, and where Molecule fits in. Molecule Labs gets a specific mention as the open data layer the ecosystem has been missing. Thanks for the write up @davewardonline.

Agentic science is moving fast. Longevity research is one of the fields where it could matter most. Renowned researcher Aubrey de Grey is bringing that question to the @DeSciBerlin main stage on June 18. Register now!